Seletalisib

Drug Profile

Seletalisib

Alternative Names: UCB-5857

Latest Information Update: 22 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator UCB
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Immunomodulators; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Immunodeficiency disorders
  • Phase II Sjogren's syndrome
  • Phase I Plaque psoriasis

Most Recent Events

  • 14 Jun 2017 Pharmacokinetics and pharmacodynamics data from Preclinical and Clinical studies in Immunodeficiency disorders presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 08 Jun 2016 Phase-III clinical trials in Immunodeficiency disorders (In adolescents, In adults) in Spain (PO) (EudraCT2015-005541-30)
  • 21 Dec 2015 Phase-I clinical trials in Immunodeficiency disorders (Activated PI3K delta syndrome) (In adolescents, In adults) in Germany (PO) (EudraCT2015-002900-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top